Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Angiotensin receptor-neprilysin inhibitor improves coronary collateral perfusion.
Li K, Kratzmann V, Dai M, Gatzke N, Rocic P, Bramlage P, Grisk O, Lubomirov LT, Hoffmeister M, Lauxmann MA, Ritter O, Buschmann E, Bader M, Persson AB, Buschmann I, Hillmeister P. Li K, et al. Among authors: buschmann e. Front Cardiovasc Med. 2023 Feb 3;9:981333. doi: 10.3389/fcvm.2022.981333. eCollection 2022. Front Cardiovasc Med. 2023. PMID: 36818914 Free PMC article.
Leukocyte telomere length and mitochondrial DNA copy number associate with endothelial function in aging-related cardiovascular disease.
Li K, Dai M, Sacirovic M, Zemmrich C, Pagonas N, Ritter O, Grisk O, Lubomirov LT, Lauxmann MA, Bramlage P, Persson AB, Buschmann E, Buschmann I, Hillmeister P. Li K, et al. Among authors: buschmann e. Front Cardiovasc Med. 2023 Jun 5;10:1157571. doi: 10.3389/fcvm.2023.1157571. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37342445 Free PMC article.
Design of the START-trial: STimulation of ARTeriogenesis using subcutaneous application of GM-CSF as a new treatment for peripheral vascular disease. A randomized, double-blind, placebo-controlled trial.
van Royen N, Piek JJ, Legemate DA, Schaper W, Oskam J, Atasever B, Voskuil M, Ubbink D, Schirmer SH, Buschmann I, Bode C, Buschmann EE. van Royen N, et al. Among authors: buschmann i, buschmann ee. Vasc Med. 2003;8(3):191-6. doi: 10.1191/1358863x03vm496oa. Vasc Med. 2003. PMID: 14989560 Clinical Trial.
START Trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease.
van Royen N, Schirmer SH, Atasever B, Behrens CY, Ubbink D, Buschmann EE, Voskuil M, Bot P, Hoefer I, Schlingemann RO, Biemond BJ, Tijssen JG, Bode C, Schaper W, Oskam J, Legemate DA, Piek JJ, Buschmann I. van Royen N, et al. Among authors: buschmann i, buschmann ee. Circulation. 2005 Aug 16;112(7):1040-6. doi: 10.1161/CIRCULATIONAHA.104.529552. Epub 2005 Aug 8. Circulation. 2005. PMID: 16087795 Clinical Trial.
Impact of the Timing of Mechanical Circulatory Support on the Outcomes in Myocardial Infarction-Related Cardiogenic Shock: Subanalysis of the PREPARE CS Registry.
Prunea DM, Bachl E, Herold L, Kanoun Schnur SS, Pätzold S, Altmanninger-Sock S, Sommer GA, Glantschnig T, Kolesnik E, Wallner M, Ablasser K, Bugger H, Buschmann E, Praschk A, Fruhwald FM, Schmidt A, von Lewinski D, Toth GG. Prunea DM, et al. Among authors: buschmann e. J Clin Med. 2024 Mar 8;13(6):1552. doi: 10.3390/jcm13061552. J Clin Med. 2024. PMID: 38541778 Free PMC article.
77 results